See more : Nanoforce, Inc. (NNFC) Income Statement Analysis – Financial Results
Complete financial analysis of BINEX Co., Ltd. (053030.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BINEX Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Kingsoft Corporation Limited (3888.HK) Income Statement Analysis – Financial Results
- Grauer & Weil (India) Limited (GRAUWEIL.BO) Income Statement Analysis – Financial Results
- Suzhou Hycan Holdings Co., Ltd. (002787.SZ) Income Statement Analysis – Financial Results
- Rimoni Industries Ltd. (RIMO.TA) Income Statement Analysis – Financial Results
- UnipolSai Assicurazioni S.p.A. (US.MI) Income Statement Analysis – Financial Results
BINEX Co., Ltd. (053030.KQ)
About BINEX Co., Ltd.
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; vitamins and nutrients; antihistamine products; antivertigo products; and OTC products. BINEX Co., Ltd. has a co-development partnership with Genexine, Inc. to develop COVID-19 vaccine. The company was founded in 1957 and is based in Incheon, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 154.82B | 156.68B | 134.40B | 132.98B | 125.26B | 104.04B | 78.03B | 80.92B | 71.14B | 57.30B | 55.13B |
| Cost of Revenue | 98.17B | 86.46B | 75.00B | 70.63B | 69.23B | 56.47B | 50.36B | 52.61B | 38.84B | 39.05B | 30.28B |
| Gross Profit | 56.66B | 70.21B | 59.40B | 62.34B | 56.03B | 47.57B | 27.67B | 28.32B | 32.29B | 18.25B | 24.85B |
| Gross Profit Ratio | 36.59% | 44.81% | 44.19% | 46.88% | 44.73% | 45.72% | 35.46% | 34.99% | 45.40% | 31.85% | 45.08% |
| Research & Development | 1.31B | 1.62B | 384.00M | 1.10B | 1.04B | 894.57M | 622.05M | 817.80M | 1.17B | 2.18B | 1.64B |
| General & Administrative | 17.02B | 4.19B | 3.89B | 3.70B | 14.42B | 13.80B | 13.08B | 12.41B | 12.76B | 12.23B | 12.33B |
| Selling & Marketing | 36.79B | 33.85B | 29.98B | 30.01B | 28.76B | 25.49B | 21.34B | 16.64B | 11.57B | 8.61B | 9.33B |
| SG&A | 53.86B | 50.93B | 45.98B | 44.67B | 43.25B | 39.44B | 34.54B | 29.20B | 24.43B | 20.83B | 21.67B |
| Other Expenses | 0.00 | -485.47M | -423.68M | -440.20M | -460.02M | -392.79M | -334.09M | -283.30M | -362.32M | 0.00 | 0.00 |
| Operating Expenses | 55.12B | 53.03B | 46.78B | 46.20B | 44.75B | 40.72B | 35.50B | 30.30B | 25.97B | 22.66B | 30.57B |
| Cost & Expenses | 153.04B | 139.50B | 121.79B | 116.84B | 113.98B | 97.19B | 85.86B | 82.91B | 64.81B | 61.71B | 60.85B |
| Interest Income | 688.66M | 824.31M | 486.91M | 337.38M | 360.21M | 1.42B | 1.51B | 1.39B | 201.71M | 1.02B | 2.01B |
| Interest Expense | 0.00 | 2.06B | 1.69B | 1.44B | 2.10B | 2.04B | 1.93B | 1.84B | 1.22B | 1.54B | 2.73B |
| Depreciation & Amortization | 9.89B | 8.30B | 6.00B | 5.68B | 9.06B | 8.98B | 8.98B | 8.08B | 6.34B | 5.95B | 3.88B |
| EBITDA | 15.85B | 25.60B | 30.93B | 13.19B | 21.72B | 15.83B | -835.54M | 6.22B | 5.17B | 1.61B | 4.08B |
| EBITDA Ratio | 10.24% | 16.26% | 13.85% | 16.41% | 16.24% | 15.22% | 1.48% | 7.53% | 17.81% | -0.52% | 7.39% |
| Operating Income | 1.78B | 17.18B | 12.61B | 16.14B | 11.28B | 6.85B | -7.83B | -1.99B | 6.33B | -6.25B | 196.24M |
| Operating Income Ratio | 1.15% | 10.96% | 9.38% | 12.14% | 9.00% | 6.58% | -10.03% | -2.46% | 8.90% | -10.90% | 0.36% |
| Total Other Income/Expenses | 3.11B | -1.95B | 11.62B | -9.93B | -657.55M | -2.05B | -3.92B | -1.72B | -8.46B | -1.32B | -7.93B |
| Income Before Tax | 4.89B | 15.23B | 23.24B | 6.08B | 10.57B | 4.80B | -11.75B | -3.70B | -2.39B | -5.43B | -7.73B |
| Income Before Tax Ratio | 3.16% | 9.72% | 17.29% | 4.57% | 8.44% | 4.61% | -15.06% | -4.58% | -3.36% | -9.48% | -14.02% |
| Income Tax Expense | 311.13M | 2.87B | 5.20B | -143.89M | 2.24B | -1.39B | -731.19M | -621.43M | 4.95B | 1.25B | 31.50M |
| Net Income | 4.67B | 12.44B | 19.09B | 6.41B | 8.50B | 6.34B | -11.29B | -3.00B | -6.81B | -4.07B | -7.44B |
| Net Income Ratio | 3.02% | 7.94% | 14.21% | 4.82% | 6.79% | 6.09% | -14.48% | -3.71% | -9.58% | -7.10% | -13.50% |
| EPS | 151.04 | 402.42 | 613.78 | 205.58 | 272.69 | 203.86 | -367.27 | -97.69 | -231.64 | -170.01 | -346.00 |
| EPS Diluted | 143.73 | 402.42 | 613.78 | 205.58 | 272.69 | 203.86 | -367.27 | -97.69 | -231.64 | -170.01 | -346.00 |
| Weighted Avg Shares Out | 30.92M | 30.92M | 31.11M | 31.19M | 31.19M | 31.09M | 30.75M | 30.76M | 29.41M | 23.93M | 21.52M |
| Weighted Avg Shares Out (Dil) | 32.50M | 30.92M | 31.11M | 31.19M | 31.19M | 31.09M | 30.75M | 30.76M | 29.41M | 23.93M | 21.52M |
Source: https://incomestatements.info
Category: Stock Reports